Polymorphism

Impact of CYP polymorphism on drug exposure

Age of patient

Age >= 2 years

Age < 2 years  ( months)

Age

months

Adult

substrate

Start typing the name of a drug or scroll down the list to choose one

CYP metabolism is a minor pathway for the elimination of this drug. No relevant interaction with CYP inhibitors or inducers is expected.
Glucuronidation is a major pathway for the elimination of this drug. No relevant interaction with CYP inhibitors is expected. Some inducers (e.g. rifampicin) may lower its exposure.

substrate

Fraction metabolized by each CYP
Adults
Children
 
Warning!

Genotypes

 

AUC ratios

Phenotype
Genotype
 
Show AUC ratios' interindividual distribution (5th to 95th percentiles)
 
Reset

Definitions

AUCEM
AUC of the substrate given alone in "extensive metabolizers"
AUCXM
AUC of the substrate given alone in patients with any other phenotype (Ultra Metabolizer, Intermediate Metabolizer, Poor Metabolizer) as defined by the genotype of the major CYP involved in the substrate metabolism